09/25/2021
Opportunity to participate in investigational asthma study “The VECTOR study” I Baytown TX and Houston. Inquest Clinical Research is looking for participants for our trial at 2656 S Loop W. Suite 560, Houston, TX 77054 and 1690 W Baker Rd, Baytown, Suit B, TX 77521. Free Medication, Test & reimbursement for their time and travel for each visit, applicable for Qualified patients. Visit our research website for more information: https://www.inquestclinicalresearch.org/ If you are interest, please contact us at (832) 606-2053- Houston and Bay Town.
Flu is a very common infection that can easily spread to other people through droplets in the air. For people with asthma, the increased inflammation of the airways caused by the flu infection may trigger an asthma attack. It could also increase our risk for other respiratory diseases such as pneumonia. This is why adolescents and young adults, even those who manage their asthma well, are encouraged to have the annual seasonal
flu vaccine to reduce their risk of having an asthma attack.
After receiving the annual flu vaccine, the body's immune system is triggered to generate
antibodies that will enable it to fight the flu virus. It usually takes about two weeks for this immune response to fully develop.
The VECTOR study is evaluating an investigational asthma study drug called tezepelumab to understand whether it affects immune response to the flu vaccine.
Clinical research studies have tested the effectiveness and safety of tezepelumab in asthma, but it is not yet approved by the
US Food and Drug Administration. This is why it is considered an investigational drug. The flu vaccine given in the VECTOR Study will be approved.